Weekly CODE chemotherapy with recombinant human granulocyte colony-stimulating factor for relapsed or refractory small cell lung cancer.

Abstract

We used cisplatin, vincristine, doxorubicin, and etoposide (CODE) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) weekly for salvage chemotherapy in relapsed or refractory small cell lung cancer (SCLC). We reviewed the medical charts of patients between January 1993 and December 1996 at the National Nishi-Gunma Hospital. Twenty patients were treated with salvage chemotherapy. The overall response rate was 55.0%. The median survival time of extensive disease patients from the start of CODE therapy was 23 weeks and the 1-year survival rate was 21.0%. Toxicities were severe, especially in myelosuppression. CODE could be selected as a salvage therapy for chemotherapy- relapsed SCLC cases.

• Authors: K Sato, S Tsuchiya, K Minato, N Sunaga, S I Ishihara, T Makimoto, I Naruse, H Hoshino, S Watanabe, R Saitoh, M Mori
• Journal: Oncology reports (Oncol Rep) 2000 Sep-Oct Vol. 7 Issue 5 Pg. 1135-9 ISSN: 1021-335X [Print] Greece
• PMID: 10948352 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor
• Vincristine
• Etoposide
• Doxorubicin
• Cisplatin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
• Carcinoma, Small Cell (drug therapy)
• Cisplatin (administration & dosage, adverse effects)
• Doxorubicin (administration & dosage, adverse effects)
• Drug Administration Schedule
• Etoposide (administration & dosage, adverse effects)
• Female
• Granulocyte Colony-Stimulating Factor (administration & dosage, adverse effects)
• Humans
• Leukopenia (chemically induced)
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Recombinant Proteins
• Salvage Therapy
• Survival Analysis
• Vincristine (administration & dosage, adverse effects)